SCHEMBL14859828

SCHEMBL14859828

Cc1ccc(C(=O)N(S)C(=O)NCc2cccc(C)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 2/20 0.47
▸ NR1H4 Q96RI1 1/20 0.46
▸ HPGD P15428 4/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CYP1A2 P05177 4/20 0.44
▸ CYP2C19 P33261 4/20 0.44
▸ TSHR P16473 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ CYP3A4 P08684 3/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14859138 0.89 NR1H4 (0.52) MMP13NR1H4HPGDHSD17B10ALDH1A1
SCHEMBL14859889 0.82 SMN1; SMN2 (0.56) HPGDALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14859932 0.81 MMP13 (0.62) MMP13HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL14860316 0.78 EPHX2 (0.59) NR1H4NPC1RAB9ACYP1A2CYP2C19
SCHEMBL14859888 0.76 NR1H4 (0.51) NR1H4ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL14859853 0.75 CYP2C9 (0.55) HPGDALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14859535 0.74 SCN5A (0.56) HPGDALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14859718 0.74 L3MBTL1 (0.56) HPGDALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL1684294 0.73 MMP13 (0.62) MMP13HPGDHSD17B10ALDH1A1KDM4E
SCHEMBL1434369 0.73 SMN1; SMN2 (0.60) MMP13HPGDHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP claimed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US claimed
EP-2583962-A2 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT Avixgen Inc. (KR) 2013-04-24 — — EP disclosed
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT AVIXGEN INC. (KR) 2013-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096138-A1 NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT UGP2, TPMT, UPP1 MMP13 4763/4885NR1H4 4314/4885HPGD 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback